[
  {
    "ts": null,
    "headline": "Top Midday Stories: Nvidia Could Get China Approval for H200 AI Chips in Q1; Defense Shares Rise After Trump Calls for 50% Raise to Military Budget",
    "summary": "The Dow Jones Industrial Average was up, the S&P 500 was roughly flat, and the Nasdaq Composite was",
    "url": "https://finnhub.io/api/news?id=268d50e388276b714f42b10c06a45f76a9205df6578165424ca36782c38721f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767891255,
      "headline": "Top Midday Stories: Nvidia Could Get China Approval for H200 AI Chips in Q1; Defense Shares Rise After Trump Calls for 50% Raise to Military Budget",
      "id": 138038267,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The Dow Jones Industrial Average was up, the S&P 500 was roughly flat, and the Nasdaq Composite was",
      "url": "https://finnhub.io/api/news?id=268d50e388276b714f42b10c06a45f76a9205df6578165424ca36782c38721f6"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Flags $1.3B Charge, Cuts Fourth-Quarter EPS Outlook",
    "summary": "Drugmaker says acquired IPR&D and milestone expenses will weigh on Q4 2025 and full-year earnings guidance.",
    "url": "https://finnhub.io/api/news?id=2d87ce5c7f6a50a477b8c1f023b7cd4c307cd0cf6cf9a0f20a261b23624054f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767884297,
      "headline": "AbbVie Flags $1.3B Charge, Cuts Fourth-Quarter EPS Outlook",
      "id": 138036621,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Drugmaker says acquired IPR&D and milestone expenses will weigh on Q4 2025 and full-year earnings guidance.",
      "url": "https://finnhub.io/api/news?id=2d87ce5c7f6a50a477b8c1f023b7cd4c307cd0cf6cf9a0f20a261b23624054f6"
    }
  },
  {
    "ts": null,
    "headline": "3 Defensive Dividend ETFs to Soften a Potential Downturn",
    "summary": "Last year marked the third straight year of double-digit gains for the S&P 500. A fourth consecutive year is far from guaranteed.",
    "url": "https://finnhub.io/api/news?id=624912924f68d09412169e149d8931abced2f966ef5ca9f6dfaab5196b5b4112",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767884160,
      "headline": "3 Defensive Dividend ETFs to Soften a Potential Downturn",
      "id": 138038371,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Last year marked the third straight year of double-digit gains for the S&P 500. A fourth consecutive year is far from guaranteed.",
      "url": "https://finnhub.io/api/news?id=624912924f68d09412169e149d8931abced2f966ef5ca9f6dfaab5196b5b4112"
    }
  },
  {
    "ts": null,
    "headline": "Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Key Labor Reports",
    "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.2% and the actively tr",
    "url": "https://finnhub.io/api/news?id=3200ed700a4dfeb643cb393a92c55432986b81e2bb292a84cd819a0fb9af4ba6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767881977,
      "headline": "Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Key Labor Reports",
      "id": 138036042,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.2% and the actively tr",
      "url": "https://finnhub.io/api/news?id=3200ed700a4dfeb643cb393a92c55432986b81e2bb292a84cd819a0fb9af4ba6"
    }
  },
  {
    "ts": null,
    "headline": "RVMD Stock Hits a Record High on Rumored Takeover Interest",
    "summary": "Revolution Medicines shares jump nearly 29% to a record high after a WSJ report said AbbVie showed takeover interest, a claim the pharma giant later denied.",
    "url": "https://finnhub.io/api/news?id=5996d2d4c5d9d92f7a59d3a3ed29abfc34279d5be0678fee5b8703faa547292d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767881460,
      "headline": "RVMD Stock Hits a Record High on Rumored Takeover Interest",
      "id": 138036587,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Revolution Medicines shares jump nearly 29% to a record high after a WSJ report said AbbVie showed takeover interest, a claim the pharma giant later denied.",
      "url": "https://finnhub.io/api/news?id=5996d2d4c5d9d92f7a59d3a3ed29abfc34279d5be0678fee5b8703faa547292d"
    }
  },
  {
    "ts": null,
    "headline": "Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked in - Wolfe",
    "summary": "Investing.com -- Wolfe is bullish on Merck & Company Inc (NYSE:MRK) while stepping back from AbbVie Inc (NYSE:ABBV). Analysts say the market is underestimating Merck’s ability to grow beyond Keytruda and has already priced in much of AbbVie’s near- and medium-term upside.",
    "url": "https://finnhub.io/api/news?id=18fee4ac493307678d6e413a3de5a44a43dcb2809d2960b53f66d8b5ef0b79ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767881018,
      "headline": "Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked in - Wolfe",
      "id": 138036624,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Investing.com -- Wolfe is bullish on Merck & Company Inc (NYSE:MRK) while stepping back from AbbVie Inc (NYSE:ABBV). Analysts say the market is underestimating Merck’s ability to grow beyond Keytruda and has already priced in much of AbbVie’s near- and medium-term upside.",
      "url": "https://finnhub.io/api/news?id=18fee4ac493307678d6e413a3de5a44a43dcb2809d2960b53f66d8b5ef0b79ad"
    }
  },
  {
    "ts": null,
    "headline": "J&J's Innovative Medicine Segment in Q4: Here's What to Watch",
    "summary": "JNJ's Innovative Medicine segment shows resilience ahead of Q4 results, with key drugs driving growth despite Stelara biosimilars and Part D headwinds.",
    "url": "https://finnhub.io/api/news?id=6504141003373658159135795e727406f16b5d90be00443478ca477255688173",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767880620,
      "headline": "J&J's Innovative Medicine Segment in Q4: Here's What to Watch",
      "id": 138036605,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "JNJ's Innovative Medicine segment shows resilience ahead of Q4 results, with key drugs driving growth despite Stelara biosimilars and Part D headwinds.",
      "url": "https://finnhub.io/api/news?id=6504141003373658159135795e727406f16b5d90be00443478ca477255688173"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Moving the Most Today: Northrop, Lockheed, Alphabet, Revolution Medicines, Costco, and More",
    "summary": "Northrop Grumman, Lockheed Martin, and RTX rally after President Donald Trump says he would hike the defense budget to $1.5 trillion next year.",
    "url": "https://finnhub.io/api/news?id=9195f07f6825b8aa39a129c41a9bbfe5883f99db36c4f8b21c5473105a510daf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767869700,
      "headline": "These Stocks Are Moving the Most Today: Northrop, Lockheed, Alphabet, Revolution Medicines, Costco, and More",
      "id": 138034904,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Northrop Grumman, Lockheed Martin, and RTX rally after President Donald Trump says he would hike the defense budget to $1.5 trillion next year.",
      "url": "https://finnhub.io/api/news?id=9195f07f6825b8aa39a129c41a9bbfe5883f99db36c4f8b21c5473105a510daf"
    }
  },
  {
    "ts": null,
    "headline": "Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates",
    "summary": "Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second quarter of 2027 Achieved development milestone for masked antibody-based program under AbbVie agreement Nominated development candidate for wholly-owned masked T cell engager program targeting CLDN18.2 Appoints Sara Bonstein as chair of board of directors WALTHAM, Mass., Jan. 08,",
    "url": "https://finnhub.io/api/news?id=fb9181de4cb8f5780b147e3ade27cfa49dbf27947faf21e072c0710c8a20d478",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767879000,
      "headline": "Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates",
      "id": 138036627,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second quarter of 2027 Achieved development milestone for masked antibody-based program under AbbVie agreement Nominated development candidate for wholly-owned masked T cell engager program targeting CLDN18.2 Appoints Sara Bonstein as chair of board of directors WALTHAM, Mass., Jan. 08,",
      "url": "https://finnhub.io/api/news?id=fb9181de4cb8f5780b147e3ade27cfa49dbf27947faf21e072c0710c8a20d478"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Denies It’s in Talks to Buy Revolution Medicines. Both Stocks Are Falling.",
    "summary": "AbbVie  on Thursday denied that it is in talks to buy cancer-drug biotech Revolution Medicines, sending both stocks lower ahead of the opening bell.  “AbbVie is not in talks to acquire Revolution Medicines,” an AbbVie spokesperson told Barron’s. The Wall Street Journal reported on Wednesday that the two companies were close to a deal, citing people familiar with the matter.  AbbVie stock fell 1.5% to $229.98 ahead of Thursday’s opening bell, having jumped 4.2% the previous session following The Journal’s report.",
    "url": "https://finnhub.io/api/news?id=4b48a95396fe1b74566a13d769696130fc3ae349ae68cf9ffdf5a0930a1c586b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767875880,
      "headline": "AbbVie Denies It’s in Talks to Buy Revolution Medicines. Both Stocks Are Falling.",
      "id": 138036628,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie  on Thursday denied that it is in talks to buy cancer-drug biotech Revolution Medicines, sending both stocks lower ahead of the opening bell.  “AbbVie is not in talks to acquire Revolution Medicines,” an AbbVie spokesperson told Barron’s. The Wall Street Journal reported on Wednesday that the two companies were close to a deal, citing people familiar with the matter.  AbbVie stock fell 1.5% to $229.98 ahead of Thursday’s opening bell, having jumped 4.2% the previous session following The Journal’s report.",
      "url": "https://finnhub.io/api/news?id=4b48a95396fe1b74566a13d769696130fc3ae349ae68cf9ffdf5a0930a1c586b"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: The Dividend Does Not Lie",
    "summary": "AbbVie's Q1 2026 dividend increases 5.5% YOY, lagging both its past growth rates and the healthcare sector median. Learn more about ABBV stock here.",
    "url": "https://finnhub.io/api/news?id=432e09225986c9347d43495ba91801f04534ddb561cb8a976fc6a215e267ee63",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767874051,
      "headline": "AbbVie: The Dividend Does Not Lie",
      "id": 138037735,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2060722585/image_2060722585.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie's Q1 2026 dividend increases 5.5% YOY, lagging both its past growth rates and the healthcare sector median. Learn more about ABBV stock here.",
      "url": "https://finnhub.io/api/news?id=432e09225986c9347d43495ba91801f04534ddb561cb8a976fc6a215e267ee63"
    }
  },
  {
    "ts": null,
    "headline": "Should Health Canada’s Eight-Week MAVIRET Approval Shape AbbVie’s (ABBV) Post-Humira Growth Story?",
    "summary": "AbbVie recently reported that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir) for treating acute and chronic hepatitis C in adults and young children, making it the first and only oral eight-week pan-genotypic regimen available in Canada. This expanded indication, granted under a Priority Review based on Phase 3 data showing high efficacy in acute hepatitis C, highlights how AbbVie’s existing portfolio can still unlock new clinical and commercial opportunities without relying...",
    "url": "https://finnhub.io/api/news?id=ac53bd52dc45f98dce3788ef64778e5f2b3d3ffcabd78a7b5f358c2877787e63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767870638,
      "headline": "Should Health Canada’s Eight-Week MAVIRET Approval Shape AbbVie’s (ABBV) Post-Humira Growth Story?",
      "id": 138034992,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie recently reported that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir) for treating acute and chronic hepatitis C in adults and young children, making it the first and only oral eight-week pan-genotypic regimen available in Canada. This expanded indication, granted under a Priority Review based on Phase 3 data showing high efficacy in acute hepatitis C, highlights how AbbVie’s existing portfolio can still unlock new clinical and commercial opportunities without relying...",
      "url": "https://finnhub.io/api/news?id=ac53bd52dc45f98dce3788ef64778e5f2b3d3ffcabd78a7b5f358c2877787e63"
    }
  },
  {
    "ts": null,
    "headline": "1 Unpopular Stock That Deserves a Second Chance and 2 We Question",
    "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
    "url": "https://finnhub.io/api/news?id=72d500c75481dfc173cf0501db77719a6505612ffd6d9fb56376ff348623e7dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767847085,
      "headline": "1 Unpopular Stock That Deserves a Second Chance and 2 We Question",
      "id": 138036629,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
      "url": "https://finnhub.io/api/news?id=72d500c75481dfc173cf0501db77719a6505612ffd6d9fb56376ff348623e7dd"
    }
  },
  {
    "ts": null,
    "headline": "Revolution Medicines (RVMD) Hits All-Time High on Buyout Buzz; Buyer Denies Talks",
    "summary": "We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Revolution Medicines, Inc. (NASDAQ:RVMD) was one of the top performers on Wednesday. Revolution Medicines soared to a new all-time high on Wednesday, as investors took path from a report from The Wall Street Journal that it was set to be acquired by AbbVie […]",
    "url": "https://finnhub.io/api/news?id=fa01a954678a29093bd9763c247074451c3b310e8ff36a0b38897b09fcb8c93b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767838683,
      "headline": "Revolution Medicines (RVMD) Hits All-Time High on Buyout Buzz; Buyer Denies Talks",
      "id": 138033078,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Revolution Medicines, Inc. (NASDAQ:RVMD) was one of the top performers on Wednesday. Revolution Medicines soared to a new all-time high on Wednesday, as investors took path from a report from The Wall Street Journal that it was set to be acquired by AbbVie […]",
      "url": "https://finnhub.io/api/news?id=fa01a954678a29093bd9763c247074451c3b310e8ff36a0b38897b09fcb8c93b"
    }
  }
]